Skip to content

ARA-290 vs BPC-157

Updated 9 sources

Key differences

  1. 1ARA-290 has Phase 2 human trials on nerve pain and nerve regrowth. BPC-157 is a broad soft-tissue repair peptide with mostly animal data.
  2. 2They are not interchangeable; ARA-290 is the narrower, better-tested tool.

Side by side

Facts from each record, in the same words as their own pages.
ARA-290 and BPC-157 side by side
ARA-290BPC-157
Category
  • Healing & recovery, Immune
  • Healing & recovery
Evidence
  • Limited human data
  • Limited human data
FDA status
  • FDA 503A Category 3Regulatory
  • Not FDA approvedRegulatory
WADA
  • Prohibited
  • Prohibited
Half-life
  • About 2 minutes in plasma; the biological effects last much longer. Plasma enzymes trim it quickly.Clinical study
  • Under 30 minutes for the intact peptide in rats and dogs. No human data. The 4-hour figure on many sites has no primary source.Competitor guide
Routes
  • Subcutaneous injection, Intravenous (IV)
  • Subcutaneous injection, Oral
Forms
  • Vial (powder)
  • Vial (powder), Capsule, Tablet
Reported doses
  • 1 to 8 mg (subcutaneous injection)
  • 2 mg (intravenous (iv))
  • 100 to 750 mcg (subcutaneous injection)
  • 1.6 to 10 mcg/kg (subcutaneous injection)
  • 250 to 1,000 mcg (oral)
Most cited frequency
  • Once daily
  • Once daily
Vial sizes
  • 10 mg, 16 mg, 5 mg, 50 mgCompetitor guide
  • 5 mg, 10 mg, 20 mg, 30 mg, 40 mgCompetitor guide
Mixed vial keeps
  • Fridge at 2 to 8 C, out of light.Competitor guide
  • Fridge at 2 to 8 C, dark, never frozen.Competitor guide
Protocols on file
  • 10
  • 23

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Competitor guide2

  1. ARA-290 peptide protocol guidepeptidedosingprotocols.com · checked Oct 24, 2026
  2. BPC-157peptidesinsider.com · checked Oct 23, 2026